Phase I/II study of 549076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.

被引：4
|
作者：
Hoang-Xuan, Khe
Hottinger, Andreas
Royer-Perron, Louis
Alentorn, Agusti
Savatovsky, Julien
De Micheli, Rita
Homicsko, Krisztian
Banquet, Sebastien
Pauly, Jeanne
Sudey, Isabelle
Tell, Roger
Therasse, Patrick
Barrie, Maryline
Campello, Chantal
Chinot, Olivier L.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2033
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A PHASE IB STUDY EVALUATING THE C-MET INHIBITOR INC280 IN COMBINATION WITH BEVACIZUMAB IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS
    Shih, Kent
    Falchook, Gerald
    Becker, Kevin
    Battiste, James
    Pearlman, Michael
    Shastry, Mythili
    Burris, Howard, III
    [J]. NEURO-ONCOLOGY, 2016, 18 : 11 - 12
  • [2] Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
    Cai, Xuezhu
    Chandra, Vyshak
    Ou, Yangming
    Emblem, Kyrre E.
    Muzikansky, Alona
    Evans, John
    Kalpathy-Cramer, Jayashree
    Dietrich, Jorg
    Chi, Andrew S.
    Wen, Patrick Y.
    Rosen, Bruce R.
    Batchelor, Tracy
    Gerstner, Elizabeth Robins
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
    Shih, Kent C.
    Patel, Manish R.
    Butowski, Nicholas A.
    Falchook, Gerald Steven
    Kizilbash, Sani Haider
    Bacha, Jeffrey A.
    Brown, Dennis
    Steino, Anne
    Schwartz, Richard Stephen
    Kanekal, Sarath
    Lopez, Lorena
    Burris, Howard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Interim Analysis of a Phase I/II Study of Panobinostat in Combination with Bevacizumab for Recurrent Glioblastoma
    Lee, Eudocia
    Reardon, David
    Schiff, David
    Drappatz, Jan
    Hammond, Samantha
    Grimm, Sean
    Norden, Andrew
    Beroukhim, Rameen
    McCluskey, Christine
    Chi, Andrew
    Batchelor, Tracy
    Doherty, Lisa
    Lafrankie, Debra
    Ruland, Sandra
    Rifenburg, Jennifer
    Jacobs, Jeanne
    Smith, Katrina
    Gaffey, Sarah
    Gerard, Mary
    Snodgrass, Susan
    Raizer, Jeffrey
    Wen, Patrick
    [J]. NEUROLOGY, 2013, 80
  • [5] Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma
    Lee, Eudocia Quant
    Reardon, David A.
    Schiff, David
    Drappatz, Jan
    Muzikansky, Alona
    Hammond, Samantha
    Grimm, Sean Aaron
    Norden, Andrew David
    Beroukhim, Rameen
    McCluskey, Christine Sceppa
    Chi, Andrew S.
    Batchelor, Tracy
    Smith, Katrina H.
    Gaffey, Sarah C.
    Gerard, Mary
    Snodgrass, Susan M.
    Raizer, Jeffrey J.
    Wen, Patrick Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Interim Analysis of a Phase I/II Study of Panobinostat in Combination with Bevacizumab for Recurrent Glioblastoma
    Lee, Eudocia
    Reardon, David
    Schiff, David
    Drappatz, Jan
    Hammond, Samantha
    Grimm, Sean
    Norden, Andrew
    Beroukhim, Rameen
    McCluskey, Christine
    Chi, Andrew
    Batchelor, Tracy
    Doherty, Lisa
    Lafrankie, Debra
    Ruland, Sandra
    Rifenburg, Jennifer
    Jacobs, Jeanne
    Smith, Katrina
    Gaffey, Sarah
    Gerard, Mary
    Snodgrass, Susan
    Raizer, Jeffrey
    Wen, Patrick
    [J]. NEUROLOGY, 2013, 80
  • [7] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    Sepulveda, J. M.
    Belda-Iniesta, C.
    Gil-Gil, M.
    Perez-Segura, P.
    Berrocal, A.
    Reynes, G.
    Gallego, O.
    Capellades, J.
    Ordonez, J. M.
    La Orden, B.
    Balana, C.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 743 - 750
  • [8] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    J. M. Sepúlveda
    C. Belda-Iniesta
    M. Gil-Gil
    P. Pérez-Segura
    A. Berrocal
    G. Reynés
    O. Gallego
    J. Capellades
    J. M. Ordoñez
    B. La Orden
    C. Balañá
    [J]. Clinical and Translational Oncology, 2015, 17 : 743 - 750
  • [9] Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor
    Park, K.
    Ciardiello, F.
    Hida, T.
    Lim, W.
    Lin, C-C.
    Murakami, H.
    Nishio, M.
    Cantero, F.
    Cattan, V.
    Gabarroca, C.
    Gandossi, E.
    Paz-Ares, L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI
    Chang, G.
    Curigliano, G.
    Lim, W.
    Viteri, S.
    Ciardiello, F.
    Hida, T.
    Lin, C.
    Murakami, H.
    Nishio, M.
    Paz-Ares, L.
    Cantero, F.
    Gabarroca, C.
    Gandossi, E.
    Kamsu-Kom, N.
    Pennaforte, S.
    Secouard-Faure, M. -.
    Park, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1847 - S1848
12345